Presentation on the biosimilar Enoxaparin of ROVI


No votes yet
 
Related
Operating revenue increased by 21% to 177.5 million euros in the first half of 2019, mainly driven by the strength of the specialty...
6 min
30/07/2019
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the conclusion of the PRISMA-3 and BORIS  studies, thus...
5 min
05/07/2019